Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: Which product type should be preferred?

Vox Sanguinis

Volumn 99, Issue 1, 2010, Pages 1-15

  Schrezenmeier, H ^a,b   Seifried, E ^a,c  

^a Red Cross Blood Service Baden Württemberg Hessen   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Adverse events; Donor complications; Platelet apheresis; Platelet concentrate; Pooled platelet concentrates

Indexed keywords

CALCIUM; CITRIC ACID; FRESH FROZEN PLASMA; THROMBOCYTE CONCENTRATE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC REACTION; ALLOIMMUNIZATION; BACTERIUM CONTAMINATION; BLOOD BANK; BLOOD DONOR; BLOOD TRANSFUSION REACTION; CLINICAL DECISION MAKING; DIZZINESS; FEBRILE NON HEMOLYTIC TRANSFUSION REACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MEDICAL PRACTICE; ORAL PARESTHESIA; PRIORITY JOURNAL; QT INTERVAL; QUALITY CONTROL; REVIEW; SHIVERING; STORAGE; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; TRANSFUSION RELATED ACUTE LUNG INJURY; TREMOR; VIRAL CONTAMINATION; CYTOLOGY; ETHICS; PHYSIOLOGY; PROCEDURES; THROMBOCYTE ACTIVATION;

BLOOD DONORS; BLOOD PLATELETS; HUMANS; PLATELET ACTIVATION; PLATELET TRANSFUSION; PLATELETPHERESIS;

EID: 77953505982     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2009.01295.x     Document Type: Review

References (126)

1. Henseler O, Heiden M, Haschberger B, Hesse J, Seitz R: Report on notifications pursuant to Section 21 German Transfusion Act for 2007. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2009 52: 715 731
2. Murphy S: Platelets from pooled buffy coats: an update. Transfusion 2005 45: 634 639
3. Andreu G, Vasse J, Sandid I, Tardivel R, Semana G: Use of random versus apheresis platelet concentrates. Transfus Clin Biol 2007 14: 514 521
4. Slichter SJ: Platelet transfusion therapy. Hematol Oncol Clin North Am 2007 21: 697 729
5. Armstrong B, Hardwick J, Raman L, Smart E, Wilkinson RW: Introduction to Blood Transfusion Technology. Vox Sang ISBT Science Series 2008 3: 165 167
6. Janetzko K, Kluter H, van WG, Eichler H: Fully automated processing of buffy-coat-derived pooled platelet concentrates. Transfusion 2004 44: 1052 1058
7. Larsson S, Sandgren P, Sjodin A, Vesterinen M, Gulliksson H: Automated preparation of platelet concentrates from pooled buffy coats: in vitro studies and experiences with the OrbiSac system. Transfusion 2005 45: 743 751
8. Ringwald J, Zimmermann R, Eckstein R: The new generation of platelet additive solution for storage at 22 degrees C: development and current experience. Transfus Med Rev 2006 20: 158 164
9. Zhang JG, Carter CJ, Culibrk B, Devine DV, Levin E, Scammell K, Weiss S, Gyongyossy-Issa MI: Buffy-coat platelet variables and metabolism during storage in additive solutions or plasma. Transfusion 2008 48: 847 856
10. Cardigan R, Sutherland J, Garwood M, Bashir S, Turner C, Smith K, Hancock V, Wiltshire M, Pergande C, Williamson LM: In vitro function of buffy coat-derived platelet concentrates stored for 9 days in CompoSol, PASII or 100% plasma in three different storage bags. Vox Sang 2008 94: 103 112
11. Dijkstra-Tiekstra MJ, Kuipers W, Setroikromo AC, de Wildt-Eggen J: Overnight or fresh buffy coat-derived platelet concentrates prepared with various platelet pooling systems. Transfusion 2008 48: 723 730
12. Levin E, Culibrk B, Gyongyossy-Issa MI, Weiss S, Scammell K, LeFresne W, Jenkins C, Devine DV: Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production. Transfusion 2008 48: 2331 2337
13. Picker SM, Radojska SM, Gathof BS: Prospective comparison of high-dose plateletpheresis with the latest apheresis systems on the same donors. Transfusion 2006 46: 1601 1608
14. Vassallo RR Jr., Wahab F, Giordano K, Murphy S: Improving technology for collecting platelets by apheresis: five-year experience in one blood center. Transfus Med Rev 2004 18: 257 266
15. Richa E, Krueger P, Burgstaler EA, Bryant SC, Winters JL: The effect of double-and triple-apheresis platelet product donation on apheresis donor platelet and white blood cell counts. Transfusion 2008 48: 1325 1332
16. Julmy F, Ammann RA, Mansouri TB, Fontana S, Hirt A, Leibundgut K: Effects of high-yield thrombocytapheresis on the quality of platelet products. Transfusion 2008 48: 442 450
17. Vasconcelos E, Figueiredo AC, Seghatchian J: Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis. Transfus Apher Sci 2003 29: 13 16
18. Krailadsiri P, Seghatchian J: Are all leucodepleted platelet concentrates equivalent? Comparison of Cobe LRS Turbo, Haemonetics MCS+ LD, and filtered pooled buffy-coat-derived platelets Vox Sang 2000 78: 171 175
19. Chabanel A, Masse M, Begue S: National French observatory of the quality of blood components for transfusion. Transfus Clin Biol 2008 15: 85 90
20. Cid J, Claparols M, Pinacho A, Hernandez JM, Ortiz P, Puig LS, Pla RP: Comparison of blood component preparation methods from whole blood bags based on buffy coat extraction. Transfus Apher Sci 2007 36: 243 247
21. Chabanel A, Carrat F, Begue S, Masse M, Perrault MP, Andreu G: Quality of leucoreduced red blood cell concentrates: 5 years of follow-up in France. Vox Sang 2008 94: 41 47
22. Andreu G, Vasse J, Herve F, Tardivel R, Semana G: Introduction of platelet additive solutions in transfusion practice. Advantages, disadvantages and benefit for patients. Transfus Clin Biol 2007 14: 100 106
23. Turner VS, Hawker RJ, Mitchell SG, Seymour Mead AM: Paired in vivo and in vitro comparison of apheresis and "recovered" platelet concentrates stored for 5 days. J Clin Apher 1994 9: 189 194
24. Arnold DM, Heddle NM, Kulczycky M, Carruthers J, Sigouin C, Blajchman MA: In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers. Transfusion 2006 46: 257 264
25. Albanyan AM, Harrison P, Murphy MF: Markers of platelet activation and apoptosis during storage of apheresis-and buffy coat-derived platelet concentrates for 7 days. Transfusion 2009 49: 108 117
26. Jilma-Stohlawetz P, Hergovich N, Homoncik M, Dzirlo L, Horvath M, Janisiw M, Panzer S, Jilma B: Impaired platelet function among platelet donors. Thromb Haemost 2001 86: 880 886
27. Anderson NA, Gray S, Copplestone JA, Chan DC, Hamon M, Prentice AG, Johnson SA, Phillips M, van WG, Oakhill A, Abeyasekera S, Pamphilon DH: A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfus Med 1997 7: 33 39
28. Kluter H, Dorges L, Maass E, Wagner T, Bartels H, Kirchner H: In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. Ann Hematol 1996 73: 85 89
29. Gmur J, von FA, Osterwalder B, Honegger H, Hormann A, Sauter C, Deubelbeiss K, Berchtold W, Metaxas M, Scali G, Frick PG: Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia. Blood 1983 62: 473 479
30. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997 337: 1861 1869
31. Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, Sher GD, Constantini LA, Patterson B, Roberts RS, Thorpe KE, Levine MN: A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002 42: 556 566
32. Strindberg J, Berlin G: Transfusion of platelet concentrates-clinical evaluation of two preparations. Eur J Haematol 1996 57: 307 311
33. Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, de LM, Lichtiger B: Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007 40: 461 464
34. Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ: Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008 48: 1447 1458
35. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R: Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005 105: 4106 4114
36. Heim D, Passweg J, Gregor M, Buser A, Theocharides A, Arber C, Meyer-Monard S, Halter J, Tichelli A, Gratwohl A: Patient and product factors affecting platelet transfusion results. Transfusion 2008 48: 681 687
37. Inverardi D, Bocchio C, Rossi L, Mazzucco L, De PL, Borzini P: Clinical, immunologic, and technical factors affecting recovery of platelet count after platelet transfusion. Haematologica 2002 87: 893 894
38. de Rie MA, van der Plas-van Dalen CM, Engelfriet CP, von dem Borne AE: The serology of febrile transfusion reactions. Vox Sang 1985 49: 126 134
39. de Korte D, Curvers J, de Kort WL, Hoekstra T, van der Poel CL, Beckers EA, Marcelis JH: Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 2006 46: 476 485
40. Enright H, Davis K, Gernsheimer T, McCullough JJ, Woodson R, Slichter SJ: Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 2003 43: 1545 1552
41. Kerkhoffs JL, Eikenboom JC, Schipperus MS, van Wordragen-Vlaswinkel RJ, Brand R, Harvey MS, de Vries RR, Barge R, van Rhenen DJ, Brand A: A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006 108: 3210 3215
42. de Wildt-Eggen J, Nauta S, Schrijver JG, van Marwijk KM, Bins M, van Prooijen HC: Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000 40: 398 403
43. Heuft HG, Mende W, Blasczyk R: A general change of the platelet transfusion policy from apheresis platelet concentrates to pooled platelet concentrates is associated with a sharp increase in donor exposure and infection rates. Transfus Med Hemother 2008 35: 106 113
44. Lopez-Plaza I, Weissfeld J, Triulzi DJ: The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 1999 39: 925 932
45. Roth WK, Weber M, Seifried E: Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999 353 (9150 359 363
46. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ: Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008 48: 1558 1566
47. Roth WK, Weber M, Buhr S, Drosten C, Weichert W, Sireis W, Hedges D, Seifried E: Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion 2002 42: 862 868
48. Chudy M, Schmidt M, Czudai V, Scheiblauer H, Nick S, Mosebach M, Hourfar MK, Seifried E, Roth WK, Grunelt E, Nubling CM: Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology 2006 44: 99 107
49. Burkhart J, Wittmann G, Howe J, Michel P, Schramm W, Weinauer F: Klebsiella pneumoniae in platelet concentrates-A case report. Transfusion Medicine and Hemotherapy 2005 32 (S1 64
50. Kopko PM, Fernando LP, Bonney EN, Freeman JL, Holland PV: HIV transmissions from a window-period platelet donation. Am J Clin Pathol 2001 116: 562 566
51. Williams AE, Thomson RA, Schreiber GB, Watanabe K, Bethel J, Lo A, Kleinman SH, Hollingsworth CG, Nemo GJ: Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997 277: 967 972
52. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP: Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004 351: 760 768
53. Roth WK, Weber M, Petersen D, Drosten C, Buhr S, Sireis W, Weichert W, Hedges D, Seifried E: NAT for HBV and anti-HBc testing increase blood safety. Transfusion 2002 42: 869 875
54. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, Busch MP: Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003 43: 696 704
55. Vamvakas EC: Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009 in press
56. Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Epstein JS, Goodman JL: Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematology (Am Soc Hematol Educ Program) 2003 575 589
57. Yomtovian R, Lazarus HM, Goodnough LT, Hirschler NV, Morrissey AM, Jacobs MR: A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993 33: 902 909
58. Leiby DA, Kerr KL, Campos JM, Dodd RY: A retrospective analysis of microbial contaminants in outdated random-donor platelets from multiple sites. Transfusion 1997 37: 259 263
59. AuBuchon JP, Cooper LK, Leach MF, Zuaro DE, Schwartzman JD: Experience with universal bacterial culturing to detect contamination of apheresis platelet units in a hospital transfusion service. Transfusion 2002 42: 855 861
60. Ness P, Braine H, King K, Barrasso C, Kickler T, Fuller A, Blades N: Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001 41: 857 861
61. Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, Schreiber GB, Arduino MJ, Holt SC, Carson LA, Banerjee SN, Jarvis WR: Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001 41: 1493 1499
62. Perez P, Salmi LR, Follea G, Schmit JL, de Barbeyrac B, Sudre P, Salamon R: Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control Study. Transfusion 2001 41: 862 872
63. Mohr H, Bayer A, Gravemann U, Muller TH: Elimination and multiplication of bacteria during preparation and storage of buffy coat-derived platelet concentrates. Transfusion 2006 46: 949 955
64. Schrezenmeier H, Walther-Wenke G, Muller TH, Weinauer F, Younis A, Holland-Letz T, Geis G, Asmus J, Bauerfeind U, Burkhart J, Deitenbeck R, Forstemann E, Gebauer W, Hochsmann B, Karakassopoulos A, Liebscher UM, Sanger W, Schmidt M, Schunter F, Sireis W, Seifried E: Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007 47: 644 652
65. Larsen CP, Ezligini F, Hermansen NO, Kjeldsen-Kragh J: Six years' experience of using the BacT/ALERT system to screen all platelet concentrates, and additional testing of outdated platelet concentrates to estimate the frequency of false-negative results. Vox Sang 2005 88: 93 97
66. Perez P, Bruneau C, Chassaigne M, Salmi LR, Noel L, Allouch P, Audurier A, Gulian C, Janus G, Boulard G, de Micco P: Multivariate analysis of determinants of bacterial contamination of whole-blood donations. Vox Sang 2002 82: 55 60
67. McDonald CP, Lowe P, Roy A, Robbins S, Hartley S, Harrison JF, Slopecki A, Verlander N, Barbara JA: Evaluation of donor arm disinfection techniques. Vox Sang 2001 80: 135 141
68. Robillard P, Naweij K, Delage G: Platelet bacterial contaminations and effectiveness of diverting the first 40 mls at whole blood donation. Transfusion 2005 45: 25a
69. de Korte D, Marcelis JH, Verhoeven AJ, Soeterboek AM: Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections. Vox Sang 2002 83: 13 16
70. Seghatchian J, de SG: Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006 35: 189 196
71. Goodrich RP, Edrich RA, Li J, Seghatchian J: The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006 35: 5 17
72. Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, Van HM, Bosly A, Lin JS, Lin L, Corash L: Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009 49: 1412 1422
73. Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP: Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion. Transfusion 2009 49: 1083 1091
74. Eder AF, Kennedy JM, Dy BA, Notari EP, Weiss JW, Fang CT, Wagner S, Dodd RY, Benjamin RJ: Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007 47: 1134 1142
75. Sintnicolaas K, Vriesendorp HM, Sizoo W, Stenfert Kroese WF, Haije WG, Hop WC, Abels J, Lowenberg B: Delayed alloimmunisation by random single donor platelet transfusions. A randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia. Lancet 1981 1: 750 754
76. Bux J, Sachs UJ: The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007 136: 788 799 (Pubitemid 46348408)
77. Win N, Chapman CE, Bowles KM, Green A, Bradley S, Edmondson D, Wallis JP: How much residual plasma may cause TRALI? Transfus Med 2008 18: 276 280
78. Eder AF, Herron R, Strupp A, Dy B, Notari EP, Chambers LA, Dodd RY, Benjamin RJ: Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007 47: 599 607
79. Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, O'Byrne MM, Evenson LK, Malinchoc M, DeGoey SR, Afessa B, Hubmayr RD, Moore SB: Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med 2007 176: 886 891
80. Trouern-Trend JJ, Cable RG, Badon SJ, Newman BH, Popovsky MA: A case-controlled multicenter study of vasovagal reactions in blood donors: influence of sex, age, donation status, weight, blood pressure, and pulse. Transfusion 1999 39: 316 320
81. Newman BH, Satz SL, Janowicz NM, Siegfried BA: Donor reactions in high-school donors: the effects of sex, weight, and collection volume. Transfusion 2006 46: 284 288
82. Tomita T, Takayanagi M, Kiwada K, Mieda A, Takahashi C, Hata T: Vasovagal reactions in apheresis donors. Transfusion 2002 42: 1561 1566
83. Wiltbank TB, Giordano GF, Kamel H, Tomasulo P, Custer B: Faint and prefaint reactions in whole-blood donors: an analysis of predonation measurements and their predictive value. Transfusion 2008 48: 1799 1808
84. Wiltbank TB, Giordano GF: The safety profile of automated collections: an analysis of more than 1 million collections. Transfusion 2007 47: 1002 1005
85. Strauss RG, Huestis DW, Wright DG, Hester JP: Cellular depletion by apheresis. J Clin Apher 1983 1: 158 165
86. Strauss RG: Apheresis donor safety-changes in humoral and cellular immunity. J Clin Apher 1984 2: 68 80
87. Koepke JA, Parks WM, Goeken JA, Klee GG, Strauss RG: The safety of weekly plateletpheresis: effect on the donors' lymphocyte population. Transfusion 1981 21: 59 63
88. Robbins G, Petersen CV, Brozovic B: Lymphocytopenia in donors undergoing regular platelet apheresis with cell separators. Clin Lab Haematol 1985 7: 225 230
89. Senhauser DA, Westphal RG, Bohman JE, Neff JC: Immune system changes in cytapheresis donors. Transfusion 1982 22: 302 304
90. Matsui Y, Martin-Alosco S, Doenges E, Christenson L, Shapiro HM, Yunis EJ, Page PL: Effects of frequent and sustained plateletapheresis on peripheral blood mononuclear cell populations and lymphocyte functions of normal volunteer donors. Transfusion 1986 26: 446 452
91. Prior CR, Coghlan PJ, Hall JM, Jacobs P: In vitro study of immunologic changes in long-term cytapheresis donors. J Clin Apher 1991 6: 69 76
92. Braine HG, Elfenbein GJ, Mellits ED: Peripheral blood lymphocyte numbers, lymphocyte proliferative responses in vitro, and serum immunoglobulins in regular hemapheresis donors. J Clin Apher 1985 2: 213 218
93. Jacobson Jl, Tetteh G, Baldwin C: Frequent apheresis collections do not adversely affect donor white blood cell counts. J Clin Apher 2006 21: 17
94. Lazarus EF, Browning J, Norman J, Oblitas J, Leitman SF: Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. Transfusion 2001 41: 756 761
95. Quiraishiy N, Notari EP, Burch JW, Eder AF, Heal J, Janas J, Miller Y, Moroff G, Siegfried B, Strupp AM, Vassallo RR, Wise E, Benjamin RJ: Impact of frequent plateletpheresis on donor platelet counts. Transfusion 2006 46: 5A
96. Zantek ND: Platelet count and donation rates of frequent plateletpheresis donors. Transfusion 2006 46: 40A
97. Vassallo RR, Murphy S: Changes in donor platelet counts with repeated plateletpheresis procedures. Transfusion 2006 46: 5A
98. Katz L, Palmer K, McDonnell E, Kabat A: Frequent plateletpheresis does not clinically significantly decrease platelet counts in donors. Transfusion 2007 47: 1601 1606
99. Strasser EF, Schuster M, Egler K, Bauer J, Weisbach V, Ringwald J, Zimmermann R, Zingsem J, Eckstein R: Frequently used plateletpheresis techniques result in variable target yields and platelet recruitment of donors. Transfusion 2005 45: 788 797
100. Stohlawetz P, Stiegler G, Jilma B, Dettke M, Hocker P, Panzer S: Measurement of the levels of reticulated platelets after plateletpheresis to monitor activity of thrombopoiesis. Transfusion 1998 38: 454 458
101. Bolan CD, Leitman SF: Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors. Blood 2002 99: 1878
102. Bolan CD, Greer SE, Cecco SA, Oblitas JM, Rehak NN, Leitman SF: Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001 41: 1165 1171
103. Bolan CD, Wesley RA, Yau YY, Cecco SA, Starling J, Oblitas JM, Rehak NN, Leitman SF: Randomized placebo-controlled study of oral calcium carbonate administration in plateletpheresis: I. Associations with donor symptoms. Transfusion 2003 43: 1403 1413
104. Bolan CD, Cecco SA, Yau YY, Wesley RA, Oblitas JM, Rehak NN, Leitman SF: Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects. Transfusion 2003 43: 1414 1422
105. Dettke M, Buchta C, Bieglmayer C, Kainberger F, Macher M, Höcker P: Short-and longterm effects of citrate on bone metabolism and bone mineral density in healthy plateletpheresis donors. J Clin Apher 2003 18: 87
106. Mercan D, Bastin G, Lambermont M, Dupont E: Importance of ionized magnesium measurement for monitoring of citrate-anticoagulated plateletpheresis. Transfusion 1997 37: 418 422
107. Dettke M, Hlousek M, Kurz M, Leitner G, Rosskopf K, Stiegler G, Stohlawetz P, Worel N, Hocker P, Panzer S: Increase in endogenous thrombopoietin in healthy donors after automated plateletpheresis. Transfusion 1998 38: 449 453
108. Tibbles HE, Navara CS, Hupke MA, Vassilev AO, Uckun FM: Thrombopoietin induces p-selectin expression on platelets and subsequent platelet/leukocyte interactions. Biochem Biophys Res Commun 2002 292: 987 991
109. Van OE, Wu YP, Pouwels JG, Ijsseldijk MJ, Sixma JJ, Akkerman JW, De Groot PG, Van WG: Thrombopoietin increases platelet adhesion under flow and decreases rolling. Br J Haematol 2003 121: 482 490
110. Bunker JP, Bendixen HH, Murphy AJ: Hemodynamic effects of intravenously administered sodium citrate. N Engl J Med 1962 266: 372 377
111. Despotis GJ, Goodnough LT, Dynis M, Baorto D, Spitznagel E: Adverse events in platelet apheresis donors: A multivariate analysis in a hospital-based program. Vox Sang 1999 77: 24 32
112. Charney DI, Salmond R: Cardiac arrest after hypertonic citrate anticoagulation for chronic hemodialysis. ASAIO Trans 1990 36: M217 M219
113. Leitman SF, Boltansky H, Alter HJ, Pearson FC, Kaliner MA: Allergic reactions in healthy plateletpheresis donors caused by sensitization to ethylene oxide gas. N Engl J Med 1986 315: 1192 1196
114. Muylle L, Baeten M, Avonts G, Peetermans ME: Anaphylactoid reaction in platelet-pheresis donor with IgE antibodies to ethylene oxide. Lancet 1986 2: 1225
115. Koch HM, Angerer J, Drexler H, Eckstein R, Weisbach V: Di(2-ethylhexyl)phthalate (DEHP) exposure of voluntary plasma and platelet donors. Int J Hyg Environ Health 2005 208: 489 498
116. Weisbach V, Koch HM, Angerer J, Eckstein R: Di(2-ethylhexyl)phthalate exposure of apheresis donors is procedure-related. Transfusion 2006 46: 1457 1458
117. Buchta C, Bittner C, Hocker P, Macher M, Schmid R, Seger C, Dettke M: Donor exposure to the plasticizer di(2-ethylhexyl)phthalate during plateletpheresis. Transfusion 2003 43: 1115 1120
118. Strauss RG: Economy of platelet transfusions from a hospital perspective: pricing predicates practice. Transfusion 2001 41: 1617 1624
119. Sweeney JD, Petrucci J, Yankee R: Pooled platelet concentrates: maybe not fancy, but fiscally sound and effective. Transfus Sci 1997 18: 575 583
120. Greinacher A, Kiefel V, Kluter H, Kroll H, Potzsch B, Riess H: Recommendations for platelet transfusion by the Joint Thrombocyte Working Party of the German Societies of Transfusion Medicine and Immunohaematology (DGTI), Thrombosis and Haemostasis Research (GTH), and Haematology and Oncology (DGHO). Dtsch Med Wochenschr 2006 131: 2675 2679
121. Eder AF, Dy BA, Kennedy JM, Notari Iv EP, Strupp A, Wissel ME, Reddy R, Gibble J, Haimowitz MD, Newman BH, Chambers LA, Hillyer CD, Benjamin RJ: The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008 48: 1809 1819
122. McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, Smith JW: Frequency of immediate adverse effects associated with apheresis donation. Transfusion 1998 38: 938 943
123. Popovsky MA: Safety of RBC apheresis and whole blood donation in allogeneic and autologous blood donors. Transfus Apher Sci 2006 34: 205 211
124. Schrezenmeier H, Wiesneth M, Reinhardt P, Sireis W, Klüter H, Seifried E: Adverse Events of Whole Blood and Plateletpheresis Donations Transf Med Hemother 2008 35 (suppl 1 34
125. Franchini M, Gandini G, Gandini AR, Crocco I, de Gironcoli M, Bertuzzo D, Giuffrida AC, Lippi G, Vassanelli A, Bressan F: Aprilli: Frequency of Adverse Events during Blood and Apheresis Donations: A Single-Center Study. Infus Ther Transfus Med 2002 29: 200 205
126. Shehata N, Kusano R, Hannach B, Hume H: Reaction rates in allogeneic donors. Transfus Med 2004 14: 327 333